Exploring polypharmacy with artificial intelligence: data analysis protocol.
Artificial intelligence
Ethics
Indicators
Medications
Polypharmacy
Social acceptability
Journal
BMC medical informatics and decision making
ISSN: 1472-6947
Titre abrégé: BMC Med Inform Decis Mak
Pays: England
ID NLM: 101088682
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
received:
19
03
2021
accepted:
12
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Polypharmacy is common among older adults and it represents a public health concern, due to the negative health impacts potentially associated with the use of several medications. However, the large number of medication combinations and sequences of use makes it complicated for traditional statistical methods to predict which therapy is genuinely associated with health outcomes. The project aims to use artificial intelligence (AI) to determine the quality of polypharmacy among older adults with chronic diseases in the province of Québec, Canada. We will use data from the Quebec Integrated Chronic Disease Surveillance System (QICDSS). QICDSS contains information about prescribed medications in older adults in Quebec collected over 20 years. It also includes diagnostic codes and procedures, and sociodemographic data linked through a unique identification number for each individual. Our research will be structured around three interconnected research axes: AI, Health, and Law&Ethics. The AI research axis will develop algorithms for finding frequent patterns of medication use that correlate with health events, considering data locality and temporality (explainable AI or XAI). The Health research axis will translate these patterns into polypharmacy indicators relevant to public health surveillance and clinicians. The Law&Ethics axis will assess the social acceptability of the algorithms developed using AI tools and the indicators developed by the Heath axis and will ensure that the developed indicators neither discriminate against any population group nor increase the disparities already present in the use of medications. The multi-disciplinary research team consists of specialists in AI, health data, statistics, pharmacy, public health, law, and ethics, which will allow investigation of polypharmacy from different points of view and will contribute to a deeper understanding of the clinical, social, and ethical issues surrounding polypharmacy and its surveillance, as well as the use of AI for health record data. The project results will be disseminated to the scientific community, healthcare professionals, and public health decision-makers in peer-reviewed publications, scientific meetings, and reports. The diffusion of the results will ensure the confidentiality of individual data.
Sections du résumé
BACKGROUND
Polypharmacy is common among older adults and it represents a public health concern, due to the negative health impacts potentially associated with the use of several medications. However, the large number of medication combinations and sequences of use makes it complicated for traditional statistical methods to predict which therapy is genuinely associated with health outcomes. The project aims to use artificial intelligence (AI) to determine the quality of polypharmacy among older adults with chronic diseases in the province of Québec, Canada.
METHODS
We will use data from the Quebec Integrated Chronic Disease Surveillance System (QICDSS). QICDSS contains information about prescribed medications in older adults in Quebec collected over 20 years. It also includes diagnostic codes and procedures, and sociodemographic data linked through a unique identification number for each individual. Our research will be structured around three interconnected research axes: AI, Health, and Law&Ethics. The AI research axis will develop algorithms for finding frequent patterns of medication use that correlate with health events, considering data locality and temporality (explainable AI or XAI). The Health research axis will translate these patterns into polypharmacy indicators relevant to public health surveillance and clinicians. The Law&Ethics axis will assess the social acceptability of the algorithms developed using AI tools and the indicators developed by the Heath axis and will ensure that the developed indicators neither discriminate against any population group nor increase the disparities already present in the use of medications.
DISCUSSION
The multi-disciplinary research team consists of specialists in AI, health data, statistics, pharmacy, public health, law, and ethics, which will allow investigation of polypharmacy from different points of view and will contribute to a deeper understanding of the clinical, social, and ethical issues surrounding polypharmacy and its surveillance, as well as the use of AI for health record data. The project results will be disseminated to the scientific community, healthcare professionals, and public health decision-makers in peer-reviewed publications, scientific meetings, and reports. The diffusion of the results will ensure the confidentiality of individual data.
Identifiants
pubmed: 34284765
doi: 10.1186/s12911-021-01583-x
pii: 10.1186/s12911-021-01583-x
pmc: PMC8290537
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
219Subventions
Organisme : Canadian Institute of Health Research
ID : CPG—170621
Informations de copyright
© 2021. The Author(s).
Références
Am J Health Syst Pharm. 2019 Jul 18;76(15):1105-1121
pubmed: 31199861
JMLR Workshop Conf Proc. 2016 Aug;56:301-318
pubmed: 28286600
Chronic Dis Inj Can. 2014 Nov;34(4):226-35
pubmed: 25408182
Int J Biostat. 2010;6(2):Article 13
pubmed: 21969997
Sci Rep. 2016 May 17;6:26094
pubmed: 27185194
MMWR Recomm Rep. 2001 Jul 27;50(RR-13):1-35; quiz CE1-7
pubmed: 18634202
Drug Saf. 2016 Feb;39(2):109-16
pubmed: 26692396
Am J Epidemiol. 1997 Jan 1;145(1):72-80
pubmed: 8982025
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Am J Public Health. 1984 Sep;74(9):979-83
pubmed: 6380323
Nat Med. 2019 Jan;25(1):44-56
pubmed: 30617339
BMC Health Serv Res. 2020 May 11;20(1):410
pubmed: 32393238
Med Care. 2018 May;56(5):441-447
pubmed: 29578951
Br J Clin Pharmacol. 2014 Sep;78(3):670-1
pubmed: 25279408
Res Social Adm Pharm. 2019 Jun;15(6):761-766
pubmed: 30249377
Cochrane Database Syst Rev. 2018 Sep 03;9:CD008165
pubmed: 30175841
Oncologist. 2020 Jan;25(1):e94-e108
pubmed: 31570516
Yonsei Med J. 2016 Jul;57(4):1016-21
pubmed: 27189299
Prev Chronic Dis. 2010 Jul;7(4):A71
pubmed: 20550829
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
JAMA. 2019 Feb 12;321(6):602-603
pubmed: 30676631
Pharmacy (Basel). 2019 Aug 29;7(3):
pubmed: 31470621
BMJ. 2017 Oct 16;359:j4587
pubmed: 29038130
Stat Med. 2004 Dec 30;23(24):3803-20
pubmed: 15580597
Chronic Dis Can. 2009;29(4):178-91
pubmed: 19804682
Health Policy. 2013 Feb;109(2):166-74
pubmed: 23195435
Soc Sci Med. 2009 Mar;68(5):919-24
pubmed: 19135288
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Ther Adv Drug Saf. 2020 Jun 12;11:2042098620933741
pubmed: 32587680
JAMA. 2016 Aug 23-30;316(8):858-71
pubmed: 27552619
JAMA Surg. 2016 Jul 1;151(7):622-30
pubmed: 26842660
Yearb Med Inform. 2018 Aug;27(1):129-139
pubmed: 30157516
J Am Med Dir Assoc. 2020 Feb;21(2):181-187
pubmed: 31926797
Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):610-8
pubmed: 25728165
Stud Health Technol Inform. 2019 Sep 3;267:52-58
pubmed: 31483254
Stat Methods Med Res. 2017 Apr;26(2):948-969
pubmed: 25519888